NASDAQ:FENC Adherex Technologies Q3 2025 Earnings Results & Report $10.18 -0.54 (-5.04%) Closing price 10/13/2026 04:00 PM EasternExtended Trading$10.18 +0.01 (+0.05%) As of 05:24 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Adherex Technologies beat analyst earnings expectations but missed on revenue in its Q3 2025 results, released November 13, 2025. The company reported EPS of -$0.02 versus the -$0.08 consensus estimate, while revenue of $12.46 million fell short of the $13.43 million estimate by $0.97 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateNovember 13, 2025TimeBefore Market OpensConference Call4:00 PM ET Adherex Technologies EPS ResultsActual EPS-$0.02Consensus EPS -$0.08Beat/MissBeat by +$0.06One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersAdherex Technologies Revenue ResultsActual Revenue$12.46 millionExpected Revenue$13.43 millionBeat/MissMissed by -$971.00 thousandYoY Revenue GrowthN/AUpcoming EarningsAdherex Technologies' Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Adherex Technologies Q3 2025 Earnings FAQ Did Adherex Technologies beat earnings estimates for Q3 2025? Adherex Technologies (NASDAQ:FENC) reported earnings of -$0.02 per share for Q3 2025, beating the consensus estimate of -$0.08. The report was announced on Thursday, November 13, 2025. What was Adherex Technologies' revenue for Q3 2025? Adherex Technologies reported revenue of $12.46 million for Q3 2025, against a consensus estimate of $13.43 million. When is Adherex Technologies' next earnings date? Adherex Technologies' next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for Adherex Technologies on the company's earnings history page. Adherex Technologies Earnings HeadlinesFennec Pharmaceuticals Announces Oral Presentation of Detailed Results from Investigator-Initiated Phase 2 STS-J01 Clinical Study of Pedmark® in Japan at SIOP 2026September 17, 2026 | globenewswire.comFennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026August 5, 2026 | globenewswire.comMy next big call (under $1)The obvious way to "bet on Trump" in crypto is the Trump memecoin. And right now it's back in the news, with a contest offering its biggest holders a seat at dinner with the President. It's also about 97% below its peak. Because a memecoin doesn't benefit from good policy. It benefits from attention. The real winners of a pro-crypto Washington are the projects with actual businesses underneath them. Ones that get more valuable as rules get clearer, institutions get comfortable, and more money flows into the market.October 14 at 1:00 AM | Crypto 101 Media (Ad)Fennec Announces Results of Annual MeetingJune 10, 2026 | globenewswire.comAdherex Technologies' PEDMARK push targets larger AYA market after record quarterMay 23, 2026 | msn.comFennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual MeetingMay 21, 2026 | globenewswire.comSee More Adherex Technologies Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Adherex Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adherex Technologies and other key companies, straight to your email. Email Address About Adherex TechnologiesAdherex Technologies (NASDAQ:FENC) was a biotechnology company that focused on developing therapies for cancer and other serious medical conditions. The company later changed its name to Fennec Pharmaceuticals, while continuing to trade under the symbol FENC. Fennec’s principal product is PEDMARK, a formulation of sodium thiosulfate designed to reduce the risk of cisplatin-induced ototoxicity, or hearing loss, in pediatric patients receiving chemotherapy. PEDMARK is administered in conjunction with cisplatin and is intended to address a significant treatment-related complication in children with cancer. The company’s activities have centered on the development, regulatory approval and commercialization of PEDMARK for pediatric oncology care. Fennec Pharmaceuticals is based in the United States and serves the pediatric cancer treatment market through commercial and healthcare relationships in North America. Adherex Technologies’ earlier development programs provided the foundation for the company’s transition into Fennec Pharmaceuticals.View Adherex Technologies ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Tax Credit Turmoil: Why Enphase and SolarEdge Face a Tough RoadSurgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?A Silent Winner: Texas Instruments Anchors the AI SupercycleDelta's Guidance Cut Could Spell Trouble for the Airline Industry Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
